1 Mansour EG, Gray R, Shatila AH, Tormey DC, Cooper MR, Osborne CK, Falkson G. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis – an intergroup study. J Clin Oncol 1998;16:3486–92.
2 Azim HA Jr, de Azambuja E, Colozza M, Bines J, Piccart MJ. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol. 2011;22(9):1939–47.
3 Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018;379(2):111–21.
4 Wong WB, Ramsey SD, Barlow WE, Garrison LP Jr, Veenstra DL. The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). Contemp Clin Trials. 2012;33:1117–23.
5 Guessous I, Mooser V, Fellay J, Bochud M, Simeoni U, Unger S, et al. Genomic medicine: the challenges of information in clinical practice. Rev Med Suisse. 2016;12(537):1838–44.
7 Jaccard E, Cornuz J, Waeber G, Guessous I. Evidence-Based Precision Medicine is Needed to Move Toward General Internal Precision Medicine. J Gen Intern Med. 2018;33(1):11–2.
8 Gaspoz JM. Smarter medicine: do physicians need political pressure to eliminate useless interventions? Swiss Med Wkly. 2015;145:w14125.